1. Home
  2. RCEL vs ACTU Comparison

RCEL vs ACTU Comparison

Compare RCEL & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • ACTU
  • Stock Information
  • Founded
  • RCEL N/A
  • ACTU 2015
  • Country
  • RCEL United States
  • ACTU United States
  • Employees
  • RCEL N/A
  • ACTU N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • ACTU
  • Sector
  • RCEL Health Care
  • ACTU
  • Exchange
  • RCEL Nasdaq
  • ACTU NYSE
  • Market Cap
  • RCEL 158.1M
  • ACTU 135.0M
  • IPO Year
  • RCEL N/A
  • ACTU 2024
  • Fundamental
  • Price
  • RCEL $5.48
  • ACTU $7.15
  • Analyst Decision
  • RCEL Strong Buy
  • ACTU Strong Buy
  • Analyst Count
  • RCEL 4
  • ACTU 1
  • Target Price
  • RCEL $16.50
  • ACTU $20.00
  • AVG Volume (30 Days)
  • RCEL 263.9K
  • ACTU 113.5K
  • Earning Date
  • RCEL 08-07-2025
  • ACTU 09-23-2025
  • Dividend Yield
  • RCEL N/A
  • ACTU N/A
  • EPS Growth
  • RCEL N/A
  • ACTU N/A
  • EPS
  • RCEL N/A
  • ACTU N/A
  • Revenue
  • RCEL $71,661,000.00
  • ACTU N/A
  • Revenue This Year
  • RCEL $57.16
  • ACTU N/A
  • Revenue Next Year
  • RCEL $36.69
  • ACTU N/A
  • P/E Ratio
  • RCEL N/A
  • ACTU N/A
  • Revenue Growth
  • RCEL 41.35
  • ACTU N/A
  • 52 Week Low
  • RCEL $4.71
  • ACTU $5.47
  • 52 Week High
  • RCEL $14.16
  • ACTU $11.99
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 51.08
  • ACTU N/A
  • Support Level
  • RCEL $5.59
  • ACTU N/A
  • Resistance Level
  • RCEL $6.35
  • ACTU N/A
  • Average True Range (ATR)
  • RCEL 0.42
  • ACTU 0.00
  • MACD
  • RCEL 0.07
  • ACTU 0.00
  • Stochastic Oscillator
  • RCEL 54.55
  • ACTU 0.00

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About ACTU ACTUATE THERAPEUTICS INC

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Share on Social Networks: